Pentavalent Antimony Associated with G-CSF in the Treatment of Cutaneous Leishmaniasis Caused by

Overview

Journal Pathogens

Date 2024 Apr 26

PMID 38668256

Authors

Carvel Suprien

Luiz H Guimaraes

Lucas P de Carvalho

Paulo R L Machado

Affiliations

Soon will be listed here.

Abstract

Methods: This study compares the effectiveness of G-CSF associated with MA in the treatment of CL. A total of 32 patients aged between 18 and 50 years with CL confirmed for were included in this study. G-CSF or placebo (0.9% saline) was applied by intralesional infiltration at four equidistant points on the edges of the largest ulcer on days 0 and 15 of treatment associated with intravenous MA.

Results: Males predominated in the G-CSF group (59%), while females predominated in the control group (53%). Injuries to the lower limbs predominated in both study groups. The cure rate in the G-CSF group was 65% and in the control group it was 47%, 90 days after initiation of therapy.

Conclusions: Our data indicate that the association of G-CSF with MA is not superior to MA monotherapy. Although not significant, the potential benefit of this combination deserves further investigation. The use of higher doses or other routes of application of G-CSF in a greater number of patients should contribute to a definitive response.

References

Rutella S, Bonanno G, Pierelli L, Mariotti A, Capoluongo E, Contemi A . Granulocyte colony-stimulating factor promotes the generation of regulatory DC through induction of IL-10 and IFN-alpha. Eur J Immunol. 2004; 34(5):1291-302. DOI: 10.1002/eji.200324651. View

Brito G, Dourado M, Guimaraes L, Meireles E, Schriefer A, de Carvalho E . Oral Pentoxifylline Associated with Pentavalent Antimony: A Randomized Trial for Cutaneous Leishmaniasis. Am J Trop Med Hyg. 2017; 96(5):1155-1159. PMC: 5417210. DOI: 10.4269/ajtmh.16-0435. View

Fine J, Manes B, Frangoul H . Systemic granulocyte colony-stimulating factor (G-CSF) enhances wound healing in dystrophic epidermolysis bullosa (DEB): Results of a pilot trial. J Am Acad Dermatol. 2015; 73(1):56-61. DOI: 10.1016/j.jaad.2015.04.015. View

Ang C, Tay Y . Hematological abnormalities and the use of granulocyte-colony-stimulating factor in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Dermatol. 2011; 50(12):1570-8. DOI: 10.1111/j.1365-4632.2011.05007.x. View

de Sica-Chapman A, Williams G, Soni N, Bunker C . Granulocyte colony-stimulating factor in toxic epidermal necrolysis (TEN) and Chelsea & Westminster TEN management protocol [corrected]. Br J Dermatol. 2009; 162(4):860-5. DOI: 10.1111/j.1365-2133.2009.09585.x. View

Bafica A, Oliveira F, Freitas L, Nascimento E, Barral A . American cutaneous leishmaniasis unresponsive to antimonial drugs: successful treatment using combination of N-methilglucamine antimoniate plus pentoxifylline. Int J Dermatol. 2003; 42(3):203-7. DOI: 10.1046/j.1365-4362.2003.01868.x. View

Sadeghian G, Nilforoushzadeh M . Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. Int J Dermatol. 2006; 45(7):819-21. DOI: 10.1111/j.1365-4632.2006.02867.x. View

Ponte-Sucre A, Gamarro F, Dujardin J, Barrett M, Lopez-Velez R, Garcia-Hernandez R . Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLoS Negl Trop Dis. 2017; 11(12):e0006052. PMC: 5730103. DOI: 10.1371/journal.pntd.0006052. View

Almeida R, DOliveira Jr A, Machado P, Bacellar O, Ko A, de Jesus A . Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous Leishmaniasis. J Infect Dis. 1999; 180(5):1735-7. DOI: 10.1086/315082. View

10.

Bunse C, Tischer S, Lahrberg J, Oelke M, Figueiredo C, Blasczyk R . Granulocyte colony-stimulating factor impairs CD8(+) T cell functionality by interfering with central activation elements. Clin Exp Immunol. 2016; 185(1):107-18. PMC: 4908295. DOI: 10.1111/cei.12794. View

11.

Weirather J, Jeronimo S, Gautam S, Sundar S, Kang M, Kurtz M . Serial quantitative PCR assay for detection, species discrimination, and quantification of Leishmania spp. in human samples. J Clin Microbiol. 2011; 49(11):3892-904. PMC: 3209110. DOI: 10.1128/JCM.r00764-11. View

12.

Carr M, Li Y, Rezakhanlou A, Ghahary A . Keratinocyte-Releasable Factors Stimulate the Expression of Granulocyte Colony-Stimulating Factor in Human Dermal Fibroblasts. J Cell Biochem. 2016; 118(2):308-317. DOI: 10.1002/jcb.25638. View

13.

Arana B, Rizzo N, Diaz A . Chemotherapy of cutaneous leishmaniasis: a review. Med Microbiol Immunol. 2002; 190(1-2):93-5. DOI: 10.1007/s004300100089. View

14.

Arevalo J, Ramirez L, Adaui V, Zimic M, Tulliano G, Miranda-Verastegui C . Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J Infect Dis. 2007; 195(12):1846-51. DOI: 10.1086/518041. View

15.

Romero G, Guerra M, Paes M, Macedo V . Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg. 2001; 65(5):456-65. DOI: 10.4269/ajtmh.2001.65.456. View

16.

Lapidari P, Vaz-Luis I, Di Meglio A . Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: A systematic review. Crit Rev Oncol Hematol. 2020; 157:103193. DOI: 10.1016/j.critrevonc.2020.103193. View

17.

Antonelli L, Dutra W, Almeida R, Bacellar O, Carvalho E, Gollob K . Activated inflammatory T cells correlate with lesion size in human cutaneous leishmaniasis. Immunol Lett. 2005; 101(2):226-30. DOI: 10.1016/j.imlet.2005.06.004. View

18.

Khoury H, Adkins D, Brown R, Vij R, Westervelt P, Trinkaus K . Adverse side-effects associated with G-CSF in patients with chronic myeloid leukemia undergoing allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2000; 25(11):1197-201. DOI: 10.1038/sj.bmt.1702423. View

19.

Santos J, de Jesus A, Machado P, Magalhaes A, Salgado K, Carvalho E . Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous Leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study. J Infect Dis. 2004; 190(10):1793-6. DOI: 10.1086/424848. View

20.

Jirmanus L, Glesby M, Guimaraes L, Lago E, Rosa M, Machado P . Epidemiological and clinical changes in American tegumentary leishmaniasis in an area of Leishmania (Viannia) braziliensis transmission over a 20-year period. Am J Trop Med Hyg. 2012; 86(3):426-33. PMC: 3284357. DOI: 10.4269/ajtmh.2012.11-0378. View